Merck, MedImmune deal space

Merck logo

Capacity issues have led to a facility relationship deal between MedImmune and Merck ($MRK). The former will provide space in its Frederick, MD, facility for bulk product manufacturing by the latter.

Under the 15-year agreement, the companies will collaborate on capacity planning, reports The Gazette. The relationship is seen as a "long-range solution dealing with capacity issues," a MedImmune spokesperson said in the article. The work has already begun.

The 385,000-square-foot Frederick facility, opened in 1999, has about 300 employees.

The companies also are evaluating Merck plants for use by AstraZeneca's ($AZN) MedImmune unit, the article notes.


Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.